Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Gail Lynn Shaw Wright, MD, FACP, FCCP is co-author of a Phase II study that examined the efficacy of administering Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer.
The inaugural Metastatic Breast Cancer Heroes™ winners were announced by CURE Media Group, recognizing individuals making a difference in the lives of those affected by metastatic breast cancer. Among the three winners is Florida Cancer Specialists & Research Institute, LLC (FCS) oncology nurse Brandi Riber, RN, based in Fort Myers.
Medical oncologist Manish R Patel, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute , LLC (FCS), first-authored a study examining dose escalation of an oral complete estrogen receptor (ER) antagonist (CERAN)/selective ER degrader (SERD) in cases of advanced and/or metastatic estrogen receptor-positive, HER2-negative breast cancer.
Medical oncologist James Reeves, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), is co-author of a study that examined the use and effectiveness of niraparib, a targeted therapy drug, to reduce the recurrence of HER2-negative, BRCA mutated breast cancer. Entitled, “Correlation Between Presence of Circulating Tumor DNA and Response to Neoadjuvant Niraparib in HER2-Negative, BRCA-Mutated Breast Cancer,” the study will be shared in a poster presentation at the San Antonio Breast Cancer Symposium being held Dec. 7 – 12, 2021.
A television commercial produced by Florida Cancer Specialists & Research Institute has been recognized in the 42nd Annual Telly Awards, which honors excellence in video and television as judged by leaders representing video platforms around the world.
Florida Cancer Specialists & Research Institute, LLC (FCS) today reported key quality and savings metrics as measured within the most recent performance period from The Centers for Medicare & Medicaid Innovation (CMMI) for the Oncology Care Model (OCM).
Gail Lynn Wright, MD Co-Authors Phase II Study Examining Trilaciclib in Treatment of Metastatic Triple-Negative Breast CancerFlorida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Gail Lynn Shaw Wright, MD, FACP, FCCP is co-author of a Phase II study that examined the efficacy of administering Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer.
FCS Physicians Present Studies in Blood Cancer Research at Hematology ExpositionPhysicians from FCS presented studies on blood cancer research at the American Society of Hematology Annual Meeting and Exposition.
Oncology Nurse Recognized as Metastatic Breast Cancer SurvivorThe inaugural Metastatic Breast Cancer Heroes™ winners were announced by CURE Media Group, recognizing individuals making a difference in the lives of those affected by metastatic breast cancer. Among the three winners is Florida Cancer Specialists & Research Institute, LLC (FCS) oncology nurse Brandi Riber, RN, based in Fort Myers.
Manish R. Patel, MD, First Author for Breast Cancer Study To Be Presented at San Antonio Breast Cancer SymposiumMedical oncologist Manish R Patel, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute , LLC (FCS), first-authored a study examining dose escalation of an oral complete estrogen receptor (ER) antagonist (CERAN)/selective ER degrader (SERD) in cases of advanced and/or metastatic estrogen receptor-positive, HER2-negative breast cancer.
James Reeves, MD Co-Authors Breast Cancer Study To Be Presented at San Antonio Breast Cancer SymposiumMedical oncologist James Reeves, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), is co-author of a study that examined the use and effectiveness of niraparib, a targeted therapy drug, to reduce the recurrence of HER2-negative, BRCA mutated breast cancer. Entitled, “Correlation Between Presence of Circulating Tumor DNA and Response to Neoadjuvant Niraparib in HER2-Negative, BRCA-Mutated Breast Cancer,” the study will be shared in a poster presentation at the San Antonio Breast Cancer Symposium being held Dec. 7 – 12, 2021.
Florida Cancer Specialists & Research Institute Television Commercial Recognized with Silver Telly AwardA television commercial produced by Florida Cancer Specialists & Research Institute has been recognized in the 42nd Annual Telly Awards, which honors excellence in video and television as judged by leaders representing video platforms around the world.
Florida Cancer Specialists & Research Institute Ranked Among Top Performing Oncology Practices in the Country for Quality & Cost Saving MeasuresFlorida Cancer Specialists & Research Institute, LLC (FCS) today reported key quality and savings metrics as measured within the most recent performance period from The Centers for Medicare & Medicaid Innovation (CMMI) for the Oncology Care Model (OCM).
Florida Cancer Specialists & Research Institute Announces Senior Leadership Promotions & AppointmentsFlorida Cancer Specialists & Research Institute (FCS) is pleased to announce the following promotions and additions to its senior leadership team.